Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy.
about
Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophyEvidence-based recommendations on topical treatment and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists.A Novel Aerosol Foam Formulation of Calcipotriol and Betamethasone Has No Impact on HPA Axis and Calcium Homeostasis in Patients With Extensive Psoriasis Vulgaris.TriCalm(®) hydrogel is significantly superior to 2% diphenhydramine and 1% hydrocortisone in reducing the peak intensity, duration, and overall magnitude of cowhage-induced itch.Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years.Managing Cushing's disease: the state of the art.Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy.DFD-01: a novel topical formulation of betamethasone dipropionate for the treatment of extensive psoriasis.Enhanced vasoconstrictor potency of the fixed combination calcipotriol plus betamethasone dipropionate in an innovative aerosol foam formulation vs. other corticosteroid psoriasis treatments.Systemic side-effects of topical corticosteroids.Pilot parallel randomised controlled trial of protective socks against usual care to reduce skin tears in high risk people: 'STOPCUTS'.Psoriatic erythroderma and hypothalamus-pituitary axis suppression due to misuse of systemic steroid: two challenging casesChange of Oral to Topical Corticosteroid Therapy Exacerbated Glucose Tolerance in a Patient with Plaque Psoriasis.Atopic Eczema: Genetic Associations and Potential Links to Developmental Exposures.Role of betamethasone valerate 2.250 mg medicated plaster in the treatment of psoriasis and other dermatological pathologies: a review
P2860
Q34207525-64BAE8E4-7994-4185-96A0-C169CCF8EDE0Q34237346-3379D62B-AC6D-4523-94C1-6AD5C9A85605Q34487520-B6250A03-7C42-456C-820F-49DCBF61F370Q35560404-11977B2A-3844-43DC-AC99-A84B62C4FF69Q35817223-A6344419-BE1C-4FD2-9A1A-C116F4E86FF1Q38177740-81938B3C-8ED6-49D1-8A11-A548F1EACF08Q38635555-495C60AF-8596-4972-9DC1-60B185185AEBQ39038227-84DB4212-69B2-453F-AC3D-5B087C68CAF2Q41905577-98FF200B-0094-48A8-86EB-444513E4D830Q41931963-79B4FAA8-A762-4166-9580-8013D4F151BDQ42689770-A2CC75C0-74FE-4F7B-B857-DF8E857A093DQ42699058-416AA4FE-8F15-46BE-8208-5F1E48F8A305Q47130756-3631A2BC-3023-410F-BD53-709D0282D24AQ50448143-5BBBF550-EE91-4B10-A7A7-F71B81EA9313Q58736314-EEE9DB24-090E-4F9D-9C5E-BA8D7B4C31FB
P2860
Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Topical corticosteroids in pla ...... suppression and skin atrophy.
@en
type
label
Topical corticosteroids in pla ...... suppression and skin atrophy.
@en
prefLabel
Topical corticosteroids in pla ...... suppression and skin atrophy.
@en
P2093
P2860
P50
P1476
Topical corticosteroids in pla ...... s suppression and skin atrophy
@en
P2093
J P Ortonne
M Le Maître
M-A Richard
P2860
P356
10.1111/J.1468-3083.2012.04523.X
P478
26 Suppl 3
P577
2012-05-01T00:00:00Z